News & Events about Jazz Pharmaceuticals Plc.
Sumitomo Mitsui Trust Holdings Inc. grew its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ Get Rating) by 0.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 176,388 shares of the ...
Pinnacle Associates Ltd. cut its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ Get Rating) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,375 shares of the specialty pharmaceutical companys stock after selling 100 shares during the ...
Ticker Report
3 months ago
Jazz Pharmaceuticals (NASDAQ:JAZZ Get Rating) had its target price boosted by The Goldman Sachs Group from $190.00 to $212.00 in a research report report published on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a buy rating on the specialty pharmaceutical company...
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating...
Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference Jazz Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN, Jan. 3, 2023 DUBLIN, Jan. 3, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced...